Dendritic spine and synapse pathology in chromatin modifier-associated autism spectrum disorders and intellectual disability.
ARID1B
KANSL1
WDR5
autism
dendritic spine
intellectual disability
synapse
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
09
2022
accepted:
05
12
2022
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Formation of dendritic spine and synapse is an essential final step of brain wiring to establish functional communication in the developing brain. Recent findings have displayed altered dendritic spine and synapse morphogenesis, plasticity, and related molecular mechanisms in animal models and post-mortem human brains of autism spectrum disorders (ASD) and intellectual disability (ID). Many genes and proteins are shown to be associated with spines and synapse development, and therefore neurodevelopmental disorders. In this review, however, particular attention will be given to chromatin modifiers such as AT-Rich Interactive Domain 1B (ARID1B), KAT8 regulatory non-specific lethal (NSL) complex subunit 1 (KANSL1), and WD Repeat Domain 5 (WDR5) which are among strong susceptibility factors for ASD and ID. Emerging evidence highlights the critical status of these chromatin remodeling molecules in dendritic spine morphogenesis and synaptic functions. Molecular and cellular insights of ARID1B, KANSL1, and WDR5 will integrate into our current knowledge in understanding and interpreting the pathogenesis of ASD and ID. Modulation of their activities or levels may be an option for potential therapeutic treatment strategies for these neurodevelopmental conditions.
Identifiants
pubmed: 36743289
doi: 10.3389/fnmol.2022.1048713
pmc: PMC9892461
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1048713Informations de copyright
Copyright © 2023 Ford, Jeon, Lee and Kim.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Autism. 2021 Mar 23;12(1):25
pubmed: 33757588
Cancer Res. 2005 Oct 15;65(20):9236-44
pubmed: 16230384
Sci Rep. 2021 Feb 16;11(1):3856
pubmed: 33594090
Front Cell Neurosci. 2018 Dec 21;12:470
pubmed: 30627085
Neuron. 2005 May 19;46(4):609-22
pubmed: 15944129
Nature. 2011 Apr 7;472(7341):120-4
pubmed: 21423168
Mol Psychiatry. 2020 Aug;25(8):1688-1703
pubmed: 31822816
Nat Neurosci. 2001 Nov;4(11):1086-92
pubmed: 11687814
Annu Rev Neurosci. 2005;28:503-32
pubmed: 16033324
Brain Sci. 2015 Mar 27;5(2):92-117
pubmed: 25826237
Clin Med (Lond). 2017 Dec;17(6):558-561
pubmed: 29196358
Neurology. 1974 Mar;24(3):203-10
pubmed: 4130661
Nat Commun. 2022 Feb 17;13(1):931
pubmed: 35177641
Genes Dev. 2014 May 1;28(9):929-42
pubmed: 24788516
Nat Neurosci. 2017 Dec;20(12):1694-1707
pubmed: 29184203
Mol Psychiatry. 2022 Jan;27(1):476-489
pubmed: 33686214
Front Pediatr. 2014 Aug 11;2:86
pubmed: 25157343
PLoS Genet. 2017 Jul 13;13(7):e1006886
pubmed: 28704368
Int J Mol Sci. 2017 Aug 30;18(9):
pubmed: 28867767
Oncol Lett. 2017 Nov;14(5):5107-5113
pubmed: 29113150
Brain Pathol. 2007 Oct;17(4):434-47
pubmed: 17919129
Neuron. 2014 Mar 19;81(6):1282-1289
pubmed: 24656250
Hum Mol Genet. 2018 Jun 15;27(12):2039-2051
pubmed: 29590342
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:30-38
pubmed: 30149092
Clin Epigenetics. 2020 Jan 10;12(1):10
pubmed: 31924266
Am J Med Genet A. 2017 Sep;173(9):2478-2484
pubmed: 28691782
EMBO Rep. 2019 Jul;20(7):e47630
pubmed: 31267707
Autism Res. 2019 Mar;12(3):401-421
pubmed: 30653853
J Clin Med. 2018 Jan 30;7(2):
pubmed: 29385767
Eur J Neurosci. 2004 Nov;20(10):2649-63
pubmed: 15548208
Nat Commun. 2022 Aug 27;13(1):5051
pubmed: 36030255
Cereb Cortex. 2000 Oct;10(10):981-91
pubmed: 11007549
Signal Transduct Target Ther. 2022 Jul 11;7(1):229
pubmed: 35817793
Autophagy. 2022 Feb;18(2):423-442
pubmed: 34286667
Elife. 2019 May 21;8:
pubmed: 31112129
Int J Mol Sci. 2021 Jul 30;22(15):
pubmed: 34360985
Mol Cell Neurosci. 2017 Jul;82:46-57
pubmed: 28476540
Open Biol. 2018 Sep;8(9):
pubmed: 30185603
EMBO J. 2007 Feb 7;26(3):752-63
pubmed: 17255939
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
Elife. 2017 Jul 11;6:
pubmed: 28695822
Eur J Hum Genet. 2016 May;24(5):652-9
pubmed: 26306646
iScience. 2019 Oct 25;20:148-167
pubmed: 31569049
J Neurosci. 2016 Mar 02;36(9):2723-42
pubmed: 26937011
Brain Pathol. 2018 Jan;28(1):3-13
pubmed: 28703923
Nat Genet. 2012 Mar 18;44(4):379-80
pubmed: 22426309
Med Genet. 2018;30(3):318-322
pubmed: 30459487
J Clin Invest. 2020 Mar 2;130(3):1431-1445
pubmed: 31794431
Neuroscientist. 2021 Feb;27(1):10-29
pubmed: 32441222
J Neurodev Disord. 2009 Sep;1(3):185-96
pubmed: 19966931
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890703
Am J Hum Genet. 2012 Mar 9;90(3):565-72
pubmed: 22405089
Mol Psychiatry. 2021 May;26(5):1429-1431
pubmed: 32601454
Biochem Biophys Res Commun. 1983 Jul 18;114(1):148-54
pubmed: 6309163
Mol Cell. 2011 Aug 5;43(3):381-91
pubmed: 21816345
Neuron. 2005 Jan 20;45(2):279-91
pubmed: 15664179
Front Cell Neurosci. 2019 Aug 20;13:385
pubmed: 31481879
Clin Genet. 2012 Sep;82(3):248-55
pubmed: 21801163
Mol Neurobiol. 2022 Aug;59(8):5104-5120
pubmed: 35672601
Nat Genet. 2012 Apr 29;44(6):636-8
pubmed: 22544367
Nat Rev Genet. 2019 Jan;20(1):7-23
pubmed: 30390049
Toxics. 2021 Dec 16;9(12):
pubmed: 34941790
J Comp Neurol. 1976 May 1;167(1):63-81
pubmed: 131810